HSCT IN PERIPHERAL VASCULAR DISEASE: A PHASE I STUDY

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。最近的研究表明，骨髓和血液中的造血干细胞可能有助于多器官系统中非造血组织的修复。在动物模型中，以及最近的有限的人类试验中，据报道，未纯化的骨髓单个核细胞和/或成人造血干细胞亚群有助于新血管的形成。由于造血干细胞(HSC)的亚群都是CD34+和AC133+，而且AC133+细胞被认为是更原始的和内皮细胞前体，本试验将利用Miltenyi CliniMACS细胞分离器分离的自体AC133+造血干细胞经皮移植给患有内科难治性和非手术性质的下肢周围血管疾病的患者。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recent studies have suggested that marrow and blood hematopoietic stem cells may contribute to non-hematopoietic tissue repair in multiple organ systems. In animal models, and more recently in limited human trials, unpurified marrow mononuclear cells and /or subsets of adult hematopoietic stem cells have been reported to contribute to neo-angiogenesis. Since the subset of hematopoietic stem cells (HSC) are both CD34+ and AC133+, and since AC133+ cells are considered more primitive and endothelial cell precursors, this trial will utilize autologous AC133+ hematopoietic stem cells isolated with the Miltenyi CliniMACS cell separator for percutaneous transplant into patients with medically refractory and non-surgical peripheral vascular disease of the lower extremity.